CHEPLAPHARM Arzneimittel GmbH

Ihre Ansprechpartner

Once again CHEPLAPHARM proves its M&A competence

Cheplapharm announces the acquisition of two product portfolios from LeoPharma and Takeda

One acquisition, a portfolio of four well established off-patent brands was acquired from LeoPharma. The four products, One-Alpha®, Pimafucin®, Locoid® and Zineryt®, are mainly focused on the therapeutic areas dermatology, gynaecology and bone disorders. With the acquisition Cheplapharm is able to expand its portfolio in Russia, France, Saudi Arabia, UK, Poland and Italy. The active pharmaceutical ingredients (“APIs”) of the products are Alfacalcidol, Hydrocortisone butyrate, Natamycin and Erythromycin together with Zinc Acetate.

The acquisition from Takeda comprises a variety of brands sold predominantly in Europe and Canada. The APIs of the portfolio are: Calcium, Candesartan, Ebrantil and Pioglitazone. The products Vipidin, Calcimagon, Candesartan, Ebrantil and Actos are focused on the therapeutic areas of cardiology and calcium-metabolism and are on sale in more than ten countries. Until the marketing authorizations of all countries have been transferred to CHEPLAPHARM, the production and distribution will be the responsibility by the seller.

“These acquisitions are the first deals with LeoPharma and Takeda, which underpins our constantly growing competence in the acquisition of new products”, said CHEPLAPHARM´s CEO Sebastian F. Braun. “Furthermore, these agreements are matching perfectly with our business strategy to further diversify our product portfolio.”

The purchase price of the first acquisition, made pursuant to an asset purchase agreement signed with LeoPharma on August 28, 2020, amounts to EUR 300m. The second acquisition was signed with Takeda on September 7, 2020, and has a purchase price of EUR 475m. Closing of both acquisitions is expected to be completed by the end of Q4 2020, subject to antitrust approvals and other customary closing conditions.

Edeltraud Lafer, Chief Operating Officer of CHEPLAPHARM concludes: “These recent acquisitions will extend our existing network and are hopefully the first step in a long relationship with the two companies.”


CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years.

Please refer to for additional information.

Nach oben expand_less